- Conditions
- Obesity
- Interventions
- CMS-recommended lifestyle counseling, Liraglutide 3.0mg, Portion-Controlled Diet, Placebo Oral Tablet, Phentermine 15 MG, Extension Study CMS-recommended lifestyle counseling
- Behavioral · Drug · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Obesity
- Interventions
- liraglutide, Placebo
- Drug · Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GLP-1 receptor agonist, Insulin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Binge-Eating Disorder
- Interventions
- Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml, Placebo
- Drug
- Lead sponsor
- Kelly Allison
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Sclerosis, Long COVID, Long Covid19, Obese, Obesity, Obesity, Morbid, Acute Leukemia in Remission
- Interventions
- Liraglutide Pen Injector [Saxenda], Medication Diary
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Obesity
- Interventions
- Saxenda, Placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metabolism and Nutrition Disorder, Obesity
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 64 more
- Conditions
- Obesity, Childhood, Neural Development
- Interventions
- Liraglutide
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut